This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garg, J. P Articles by Bakris, G. L Search for Related Content PubMed PubMed Citation Articles by Garg, J. P Articles by Bakris, G. L Social Bookmarking                   What's this?

Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease

Rush Presbyterian/St Luke’s Medical Center, Department of Preventive Medicine, Hypertension/Clinical Research Center, Chicago, IL, USA

George L Bakris

Rush Presbyterian/St Luke’s Medical Center, Department of Preventive Medicine, Hypertension/Clinical Research Center, Chicago, IL, USA, gbakrisKrush.edu

Based on the data from large single and multi-center clinical trials, including the Heart Outcomes Prevention Evaluation (HOPE) study, it is clear that the presence of microalbuminuria is a signal from the kidney that cardiovascular risk is increased and that vascular responses are altered. This is exemplified by studies that have demonstrated that the compensatory vaso-dilation seen following relief from prolonged ischemia or infusion of vasodilators such as nitroglycerin is blunted in people with microalbuminuria. Thus, the presence of between 30 and 299 mg/day of albumin in the urine is associated with abnormal vascular responsiveness, which may be the result of more advanced atherosclerosis and not necessarily related to the presence of hypertension or renal disease. Agents known to reduce the rise in microalbuminuria or actually reduce the level of microalbuminuria, such as ACE inhibitors, angiotensin receptor blockers, HMG-CoA reductase inhibitors, beta blockers, non-dihydropyridine calcium channel blockers and diuretics, have all been shown to reduce cardiovascular mortality and in some cases preserve renal function. This article will present an overview of the data that support the assertion that a reduction in the rise of microalbuminuria is a significant consideration in the selection of agents to treat a given risk factor (cholesterol or blood pressure) to a recommended target goal. Achieving such a goal with agents that also impact microalbuminuria will provide for a more complete cardiovascular risk reduction.

Key Words: ACE inhibitors • angiotensin II receptor blockers • cardiovascular disease • diabetes mellitus • hypertension • microalbuminuria • nephropathy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]

				G. L. Bakris Protein Kinase C-{beta} Inhibition: A Promise Not Yet Fulfilled Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 619 - 620. [Full Text] [PDF]

				S.-i. Araki, M. Haneda, D. Koya, H. Hidaka, T. Sugimoto, M. Isono, K. Isshiki, M. Chin-Kanasaki, T. Uzu, and A. Kashiwagi Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Diabetes, June 1, 2007; 56(6): 1727 - 1730. [Abstract] [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes--2007 Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41. [Full Text] [PDF]

				N. Khosla and G. Bakris Lessons Learned from Recent Hypertension Trials about Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 229 - 235. [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]

				A. Nakamura, K. Shikata, M. Hiramatsu, T. Nakatou, T. Kitamura, J. Wada, T. Itoshima, and H. Makino Serum Interleukin-18 Levels Are Associated With Nephropathy and Atherosclerosis in Japanese Patients With Type 2 Diabetes Diabetes Care, December 1, 2005; 28(12): 2890 - 2895. [Abstract] [Full Text] [PDF]

				G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, B. Waterhouse, M. A. Lukas, et al. Differential Effects of {beta}-Blockers on Albuminuria in Patients With Type 2 Diabetes Hypertension, December 1, 2005; 46(6): 1309 - 1315. [Abstract] [Full Text] [PDF]

				S.-i. Araki, M. Haneda, T. Sugimoto, M. Isono, K. Isshiki, A. Kashiwagi, and D. Koya Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes Diabetes, October 1, 2005; 54(10): 2983 - 2987. [Abstract] [Full Text] [PDF]

				S. Nathan, C. J. Pepine, and G. L. Bakris Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients Hypertension, October 1, 2005; 46(4): 637 - 642. [Abstract] [Full Text] [PDF]

				J. Lea, T. Greene, L. Hebert, M. Lipkowitz, S. Massry, J. Middleton, S. G. Rostand, E. Miller, W. Smith, G. L. Bakris, et al. The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease: Results of the African American Study of Kidney Disease and Hypertension Arch Intern Med, April 25, 2005; 165(8): 947 - 953. [Abstract] [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36. [Full Text] [PDF]

				G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial JAMA, November 10, 2004; 292(18): 2227 - 2236. [Abstract] [Full Text] [PDF]

				K. Abbott, E. Basta, and G. L. Bakris Blood Pressure Control and Nephroprotection in Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438. [Abstract] [Full Text] [PDF]

				G. M. Chertow A 43-Year-Old Woman With Chronic Renal Insufficiency JAMA, March 10, 2004; 291(10): 1252 - 1259. [Full Text] [PDF]

				A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, December 1, 2003; 42(6): 1206 - 1252. [Abstract] [Full Text] [PDF]

				B. I. Freedman, S. R. Beck, S. S. Rich, G. Heiss, C. E. Lewis, S. Turner, M. A. Province, K. L. Schwander, D. K. Arnett, and B. G. Mellen A Genome-Wide Scan for Urinary Albumin Excretion in Hypertensive Families Hypertension, September 1, 2003; 42(3): 291 - 296. [Abstract] [Full Text] [PDF]

				K. Rossing, P. K. Christensen, S. Andersen, P. Hovind, H. P. Hansen, and H.-H. Parving Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure: A substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Diabetes Care, March 1, 2003; 26(3): 569 - 574. [Abstract] [Full Text] [PDF]